Colorectal cancer (CRC) is among the most common malignancies and is the second leading cause of cancer-related morbidity and mortality. CRC arises from a multistep sequence of genetic alterations that result in the transformation of normal mucosa to a precursor adenoma and ultimately to carcinoma. Currently, there is no early diagnostic test with high sensitivity, specificity and positive predictive value, which can be used as a routine screening tool. Therefore, there is a need for new biomarkers for colorectal cancer that can improve early diagnosis, monitoring of disease progression and therapeutic response and detect disease reoccurrence. In recent years, a multiplicity of markers has been proposed for CRC. These markers can be measured in serum, tissue or stools while the others included are known as risk biomarkers, biomarkers in tumorstaging and chemopreventive trials.